Taiho Pharma Singapore Pte. Ltd. has appointed Zuellig Pharma Malaysia as the sole distributor for TAS-102 (trifluridine and tipiracil, marketed under brand name "Lonsurf®" in Japan, USA and Europe) – a colorectal cancer treatment product in Malaysia.

TAS-102 is a prescription oral therapy for patients with colorectal cancer who have failed to respond to standard chemotherapies.

“Taiho Pharmaceutical is a leading manufacturer of oncology products and we are proud to be working with them to bring TAS-102 to the people in Malaysia,” Zuellig Pharma Malaysia Chief Executive Garcia Santiago said.

Yoshimasa Nishimura , Managing Director of Taiho Pharma Singapore said: “We are pleased to be working with Zuellig Pharma. Its long history and reach in Malaysia together with its strong relationships with the medical community will allow us to make TAS-102 available to help people across the country.”

Taiho Pharma Singapore plans to file new drug application for TAS-102 in Malaysia in 2017.